<DOC>
	<DOCNO>NCT02341547</DOCNO>
	<brief_summary>This prospective , observational , non-inferior study ESRF patient stable Eprex switch Biosimilar Epoetin Alfa . Study plan recrut 44 patient . Following recruitment , baseline data collection full routine laboratory test switch Binocrit.Primary endpoint Mean change haemoglobin level 12 week Secondary endpoint Mean change haemoglobin level 6 week Safety endpoint Adverse drug reaction serious adverse effect Analysis : Changes baseline Week 6 Week 12 evaluate use pair t-test Wilcoxon sign rank test appropriate . Changes continuous variable time evaluate use repeated-measures analysis variance . Patients iron-deficiency ( ferritin &lt; 100 ng/ml transferrin saturation &lt; 20 % ) analyse separately</brief_summary>
	<brief_title>Effectiveness Biosimilar Epoetin Alfa Stable 'End Stage Renal Failure '</brief_title>
	<detailed_description>Anaemia CKD associate reduce quality life increase cardiovascular disease , hospitalization , cognitive impairment , mortality . Correcting anaemia consider important part slow even stop progression CKD . Recombinant human erythropoietin ( EPO ) epoetin alfa erythropoiesis-stimulating agent ( ESAs ) important treatment option . The ESA currently use hospital Eprex® , recombinant human EPO epoetin alfa soon replace Binocrit® , biosimilar ESA approve European Medicines Agency ( EMA ) . We want see whether maintenance haemoglobin stable ESRF patient would affect switch real life practice Malaysian population . This prospective , observational , non-inferiority study ESRF patient stable Eprex switch Bio similar Epoetin Alfa . Study population 44 End stage renal failure patient Penang Seberang Jaya hospital.Following recruitment , baseline data collection full routine laboratory test switch Bio similar Epoetin Alfa .Primary endpoint Mean change haemoglobin level 6 week Secondary endpoint Mean change haemoglobin level 12 week Safety endpoint Adverse drug reaction serious adverse effect Analysis : Changes baseline Week 6 Week 12 evaluate use pair t-test Wilcoxon sign rank test appropriate . Changes continuous variable time evaluate use repeated-measures analysis variance . Patients iron-deficiency ( ferritin &lt; 100 ng/ml transferrin saturation &lt; 20 % ) analyse separately</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . End Stage Renal Failure ( ESRF ) patient 3x per week HD least 6 month plan conversion Binocrit 2 . Stable dose Eprex iron least 3 month 3 . No active bleeding 1 . Allergy erythropoietin 2 . Bone marrow disorder 3 . Acute/chronic bleed 4 . Acute illness require hospitalization within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>